Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC
Status:
Withdrawn
Trial end date:
2019-09-06
Target enrollment:
Participant gender:
Summary
Fruquintinib administered at 4 mg once daily in cycle 1 and 5 mg once daily in followed
cycles (3 weeks on and 1 week off, 4 weeks as 1 cycle) was well tolerated and demonstrated
encouraging preliminary clinical antitumor activity in patients with advanced NSCLC in phase
II study.
This study is aimed to evaluate the efficacy and safety of Fruquintinib in the treatment of
high risk patients with advanced NSCLC who is > 75 years, or Eastern Cooperative Oncology
Group (ECOG) Performance Status (PS) = 2, or without systemic chemotherapy, or with at least
three lines systemic chemotherapies.